ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,063.20
      0.01%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,499.00
      0.03%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. Biohaven Ltd (BHVN)

      7. Biohaven Ltd (BHVN) News

      BHVN

      Biohaven (BHVN)

      Biohaven Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:BHVN
      DateTimeSourceHeadlineSymbolCompany
      05/29/20247:30AMPR Newswire (US)Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D DayNYSE:BHVNBiohaven Ltd
      05/29/20247:15AMPR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNYSE:BHVNBiohaven Ltd
      05/17/20244:42PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      05/17/20244:41PMEdgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
      05/09/20244:16PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:BHVNBiohaven Ltd
      05/09/20244:14PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      05/09/20244:05PMPR Newswire (US)Biohaven Reports First Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
      04/22/20244:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
      04/17/20244:05PMPR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
      04/13/20249:00AMPR Newswire (US)Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business UpdatesNYSE:BHVNBiohaven Ltd
      02/29/20244:16PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      02/29/20244:05PMPR Newswire (US)Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
      01/08/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      01/08/20247:30AMPR Newswire (US)Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncoloNYSE:BHVNBiohaven Ltd
      01/02/20247:00AMPR Newswire (US)Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
      12/01/20234:30PMPR Newswire (US)Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingNYSE:BHVNBiohaven Ltd
      11/14/20234:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
      11/14/20234:05PMPR Newswire (US)Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
      10/16/20237:00AMPR Newswire (US)Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®NYSE:BHVNBiohaven Ltd
      10/05/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      10/05/20234:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
      10/04/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
      10/02/202311:56PMPR Newswire (US)Biohaven Announces Pricing of $225 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
      10/02/20239:41PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      10/02/20235:09PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
      10/02/20235:07PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
      10/02/20234:36PMPR Newswire (US)BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARESNYSE:BHVNBiohaven Ltd
      10/02/20234:01PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:BHVNBiohaven Ltd
      09/27/20236:58AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      09/14/20237:00AMPR Newswire (US)Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular AtrophyNYSE:BHVNBiohaven Ltd
       Showing the most relevant articles for your search:NYSE:BHVN